Esvy Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 2.50 Cr
- Paid Up Capital ₹ 1.14 Cr
- Company Age 5 Year, 5 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth 108.73%
- Profit Growth 385.84%
- Ebitda 382.46%
- Net Worth 17.71%
- Total Assets 21.82%
About Esvy Life Sciences
Esvy Life Sciences Private Limited (ELSPL) is a Private Limited Indian Non-Government Company incorporated in India on 13 August 2019 (Five years and five months 22 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 Cr and a paid-up capital of Rs 1.14 Cr, as per Ministry of Corporate Affairs (MCA) records.
Company Details
-
Location
Hyderabad, Telangana, India
-
Telephone
+91-XXXXXXXXXX
-
Email Address
-
Website
-
Social Media-
Corporate Identity Details
-
CIN/LLPIN
U24230TG2019PTC134767
-
Company No.
134767
-
Company Classification
Private Limited Indian Non-Government Company
-
Incorporation Date
13 Aug 2019
-
Date of AGM
30 Sep 2023
-
Date of Balance Sheet
31 Mar 2023
-
Listing Status
Unlisted
-
ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Esvy Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Prabhu Gajawada
|
Director | 13-Aug-2019 | Current |
|
Neeraja Peddi
|
Director | 13-Aug-2019 | Current |
Financial Performance of Esvy Life Sciences.
Esvy Life Sciences Private Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 108.73% increase. The company also saw a substantial improvement in profitability, with a 385.84% increase in profit. The company's net worth Soared by an impressive increase of 17.71%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
|
(FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
|
||||||
| Revenue from Operations |
|
||||||
| Total Assets |
|
||||||
| Profit or Loss |
|
||||||
| Net Worth |
|
||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Esvy Life Sciences?
In 2023, Esvy Life Sciences had a promoter holding of 44.74% and a public holding of 55.26%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
-
Adwagons Advertising Private LimitedPrabhu Gajawada is a mutual person
-
Esvy Purple Private LimitedNeeraja Peddi and Prabhu Gajawada are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Esvy Life Sciences?
Unlock and access historical data on people associated with Esvy Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Esvy Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Esvy Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.